The Hippo transducers TAZ and YAP in breast cancer: Oncogenic activities and clinical implications

Expert Reviews in Molecular Medicine

Volumn 17, Issue , 2015, Pages

  Maugeri Saccà, Marcello ^a   Barba, Maddalena ^a   Pizzuti, Laura ^a   Vici, Patrizia ^a   Di Lauro, Luigi ^a   Dattilo, Rosanna ^b   Vitale, Ilio ^a   Bartucci, Monica ^c   Mottolese, Marcella ^a   De Maria, Ruggero ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HIPPO PROTEIN; ONCOPROTEIN; REGULATOR PROTEIN; TRANSCRIPTIONAL CO ACTIVATOR WITH PDZ BINDING MOTIF PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TAZ PROTEIN, HUMAN; TRANSCRIPTION FACTOR; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER PROGNOSIS; CANCER RESEARCH; CANCER RESISTANCE; CANCER STEM CELL; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEOPLASTIC STEM CELLS; PHOSPHOPROTEINS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84989797376     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/erm.2015.12     Document Type: Review

References (108)

1. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 3.2014. Available at: http://www.nccn. org/professionals/physician-gls/f-guidelines.asp
2. Perou C.M. (2000) Molecular portraits of human breast tumours. Nature 406, 747-752
3. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70
4. Johnson R. and Halder G. (2014) The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nature Reviews Drug Discovery13, 63-79
5. Justice R.W. et al. (1995) The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes & Development 9, 534-546
6. Xu T. et al. (1995) Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase. Development 121, 1053-1063
7. Pantalacci S. et al. (2003) The Salvador partner Hippo promotes apoptosis and cell-cycle exit in Drosophila. Nature Cell Biology 5, 921-927
8. Udan R.S. et al. (2003) Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway. Nature Cell Biology 5, 914-920
9. Wu S. et al. (2003) Hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell 114, 445-456
10. Jia J. et al. (2003) The Drosophila Ste20 family kinase dMST functions as a tumor suppressor by restricting cell proliferation and promoting apoptosis. Genes & Development 17, 2514-2519
11. Tapon N. et al. (2002) Salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell 110, 467-478
12. Harvey K.F. (2003) The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell 114, 457-467
13. Hamaratoglu F. et al. (2006) The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol 8, 27-36
14. Camargo F.D. et al. (2007) YAP1 increases organ size and expands undifferentiated progenitor cells. Current Biology 17, 2054-2060
15. Zhao B. et al. (2007) Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes & Development 21, 2747-2761
16. Wu S. et al. (2008) The TEAD/TEF family protein Scalloped mediates transcriptional output of the Hippo growth-regulatory pathway. Developmental Cell 14, 388-398
17. Zhang L. et al. (2008) The TEAD/TEF family of transcription factor Scalloped mediates Hippo signaling in organ size control. Developmental Cell 14, 377-387
18. Zhou D. et al. (2009) Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 16, 425-438
19. Fernández B.G. et al. (2011) Actin-Capping Protein and the Hippo pathway regulate F-actin and tissue growth in Drosophila. Development 138, 2337-2346
20. Sansores-Garcia L. et al. (2011) Modulating F-actin organization induces organ growth by affecting the Hippo pathway. EMBO J 30, 2325-2335
21. Harvey K.F., Zhang X. and Thomas D.M. (2013) The Hippo pathway and human cancer. Nature Reviews Cancer 13, 246-257
22. Dong J. et al. (2007) Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 130, 1120-1133
23. Huang J. et al. (2005) The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila homolog of YAP. Cell 122, 421-434
24. Lei Q.Y. et al. (2008) TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Molecular and Cellular Biology 28, 2426-2436
25. Piccolo S., Dupont S. and Cordenonsi M. (2014) The biology of YAP/TAZ: Hippo signaling and beyond. Physiological Reviews 94, 1287-1312
26. Hong W. and Guan K.L. (2012) The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Seminars in Cell and Developmental Biology 23, 785-793
27. Liu C.Y. et al. (2010) The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF{beta}-TrCP E3 ligase. Journal of Biological Chemistry 285, 37159-37169
28. Zhao B. et al. (2010) A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes & Development 24, 72-85
29. Dupont S. et al. (2011) Role of YAP/TAZ in mechanotransduction. Nature 474, 179-183
30. Sorrentino G. et al. (2014) Metabolic control of YAP and TAZ by the mevalonate pathway. Nature Cell Biology 16, 357-366
31. Azzolin L. et al. (2014) YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response. Cell 158, 157-170
32. Bartucci M. et al. (2015) TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene 34, 681-690
33. Vici P. et al. (2014) The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. Oncotarget 5, 9619-9625
34. Lehn S. et al. (2014) Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response. BMC Cancer 14, 119
35. Min Kim H. et al. (2014) Metaplastic carcinoma show different expression pattern of YAP compared to triple-negative breast cancer. Tumor Biology 36, 1207-1212
36. Kim S.K. et al. (2014) Yes-associated protein (YAP) is differentially expressed in tumor and stroma according to the molecular subtype of breast cancer. International Journal of Clinical and Experimental Pathology 7, 3224-3234
37. Skibinski A. et al. (2014) The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment. Cell Reports 6, 1059-1072
38. Chan S.W. et al. (2008) A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Research 68, 2592-2598
39. Chan S.W. et al. (2009) TEADs mediate nuclear retention of TAZ to promote oncogenic transformation. The Journal of Biological Chemistry 284, 14347-14358
40. Zhao D., Zhi X., Zhou Z. and Chen C. (2012) TAZ antagonizes the WWP1-mediated KLF5 degradation and promotes breast cell proliferation and tumorigenesis. Carcinogenesis 33, 59-67
41. Habbig S. et al. (2011) NPHP4, a cilia-associated protein, negatively regulates the Hippo pathway. The Journal of Cell Biology 193, 633-642
42. Habbig S. et al. (2012) The ciliopathy disease protein NPHP9 promotes nuclear delivery and activation of the oncogenic transcriptional regulator TAZ. Human Molecular Genetics 21, 5528-5538
43. Hiemer S.E., Szymaniak A.D. and Varelas X. (2014) The transcriptional regulators TAZ and YAP direct transforming growth factor β-induced tumorigenic phenotypes in breast cancer cells. Journal of Biological Chemistry 289, 13461-13474
44. Overholtzer M. et al. (2006) Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proceedings of the National Academy of Sciences of the United States of America 103, 12405-12410
45. Wang X., Su L. and Ou Q. (2012) Yes-associated protein promotes tumour development in luminal epithelial derived breast cancer. European Journal of Cancer 48, 1227-1234
46. Chen Q. et al. (2014) A temporal requirement for Hippo signaling in mammary gland differentiation, growth, and tumorigenesis. Genes & Development 28, 432-437
47. Zhang J. et al. (2009) YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nature Cell Biology 11, 1444-1450
48. Yang N. et al. (2012) TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin. Cell Cycle 11, 2922-2930
49. Bendinelli P. et al. (2013) Hypoxia inducible factor-1 is activated by transcriptional co-activator with PDZ-binding motif (TAZ) versus WWdomain-containing oxidoreductase (WWOX) in hypoxic microenvironment of bone metastasis from breast cancer. European Journal of Cancer 49, 2608-2618
50. Lamar J.M. et al. (2012) The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proceedings of the National Academy of Sciences of the United States of America 109, E2441-E2450
51. Chen D. et al. (2012) LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nature Medicine 18, 1511-1517
52. Madar S., Goldstein I. and Rotter V. (2013) 'Cancer associated fibroblasts'-more than meets the eye. Trends in Molecular Medicine 19, 447-453
53. Calvo F. et al. (2013) Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nature Cell Biology 15, 637-646
54. Shao D.D. et al. (2014) KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 158, 171-184
55. Kapoor A. et al. (2014) Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell 158, 185-197
56. Basu S. et al. (2003) Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Molecular Cell 11, 11-23
57. Matallanas D. et al. (2007) RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Molecular Cell 27, 962-975
58. Strano S. et al. (2005) The transcriptional coactivator Yesassociated protein drives p73 gene-target specificity in response to DNA Damage. Molecular Cell 18, 447-459
59. Yuan M. et al. (2008) Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death & Differentiation 15, 1752-1759
60. Danovi S.A. et al. (2008) Yes-associated protein (YAP) is a critical mediator of c-Jun-dependent apoptosis. Cell Death & Differentiation 15, 217-219
61. Levy D. et al. (2007) The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73. Cell Death & Differentiation 14, 743-751
62. Strano S. et al. (2001) Physical interaction with Yes-associated protein enhances p73 transcriptional activity. Journal of Biological Chemistry 276, 15164-15173
63. Carter S.L. et al. (1994) Loss of heterozygosity at 11q22-q23 in breast cancer. Cancer Research 54, 6270-6274
64. Gudmundsson J. et al. (1995) Loss of heterozygosity at chromosome 11 in breast cancer: association of prognostic factors with genetic alterations. British Journal of Cancer 72, 696-701
65. Hampton G.M. et al. (1994) Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3. Cancer Research 54, 4586-4589
66. Winqvist R. et al. (1995) Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis. Cancer Research 55, 2660-2664
67. Yu S.J. et al. (2013) MicroRNA-200a promotes anoikis resistance and metastasis by targeting YAP1 in human breast cancer. Clinical Cancer Research 19, 1389-1399
68. Bonnet D. and Dick J.E. (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine 3, 730-737
69. Al-Hajj M. et al. (2003) Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 100, 3983-3988
70. Ricci-Vitiani L. et al. (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445, 111-115
71. Eramo A. et al. (2008) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death & Differentiation 15, 504-514
72. Singh S.K. et al. (2004) Identification of human brain tumour initiating cells. Nature 432, 396-401
73. TodaroM. et al. (2010) Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Research 70, 8874-8885
74. Prince M.E. et al. (2007) Identification of a subpopulation of cells with cancer stem cell properties inhead and neck squamous cell carcinoma. Proceedings of the National Academy of Sciences of the United States of America 104, 973-978
75. Li C. et al. (2007) Identification of pancreatic cancer stem cells. Cancer Research 67, 1030-1037
76. Collins A.T. et al. (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Research 65, 10946-10951
77. Gao M.Q. et al. (2010) CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 29, 2672-2680
78. GreavesM. and Maley C.C. (2012) Clonal evolution in cancer. Nature 481, 306-313
79. Dieter S.M. et al. (2011) Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 9, 357-365
80. Piccirillo S.G. et al. (2009) Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution. Oncogene 28, 1807-1811
81. Anderson K. et al. (2011) Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469, 356-361
82. Notta F. et al. (2011) Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 469, 362-367
83. Mani S.A. et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715
84. Li Z. et al. (2009) Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15, 501-513
85. Hjelmeland A.B. et al. (2011) Acidic stress promotes a glioma stem cell phenotype. Cell Death & Differentiation 18, 829-840
86. Todaro M. et al. (2014) CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell 14, 342-356
87. Mo J.S., Park H.W. and Guan K.L. (2014) The Hippo signaling pathway in stem cell biology and cancer. EMBO Reports 15, 642-656
88. Cordenonsi M. et al. (2011) The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147, 759-772
89. Maugeri-Saccà M., Zeuner A. and De Maria R. (2011) Therapeutic targeting of cancer stem cells. Frontiers in Oncology 1, 10 doi: 10.3389/fonc.2011.00010
90. Lai D., Ho K.C., Hao Y. and Yang X. (2011) Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Research 71, 2728-2738
91. Li Y.W. et al. (2015) Characterization of TAZ domains important for the induction of breast cancer stem cell properties and tumorigenesis. Cell Cycle 14, 146-156
92. Xiang L. et al. (2014) Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype. Oncotarget 5, 12509-12527
93. Chang C. et al. (2015) A laminin 511 matrix is regulated by TAZ and functions as the ligand for the a6Bβ1 integrin to sustain breast cancer stem cells. Genes & Development 29, 1-6
94. Frangou C. et al. (2014) Molecular profiling and computational network analysis of TAZ-mediated mammary tumorigenesis identifies actionable therapeutic targets. Oncotarget 5, 12166-12176
95. Maugeri-Saccà M., Vigneri P. and De Maria R. (2011) Cancer stem cells and chemosensitivity. Clinical Cancer Research 17, 4942-4947
96. Maugeri-Saccà M., Bartucci M. and De Maria R. (2012) DNA damage repair pathways in cancer stem cells. Molecular Cancer Therapeutics 11, 1627-1636
97. Reis-Filho J.S. and Pusztai L. (2011) Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 378, 1812-1823
98. Serrano I. et al. (2013) Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase. Nature Communications 4, 2976
99. Matteucci E. et al. (2013) Bone metastatic process of breast cancer involves methylation state affecting E-cadherin expression through TAZ and WWOX nuclear effectors. European Journal of Cancer 49, 231-244
100. Baselga J. et al. (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379, 633-640
101. Untch M. et al. (2012) Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. The Lancet Oncology 13, 135-144
102. Gianni L. et al. (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. The Lancet Oncology 13, 25-32
103. Fumagalli D. (2012) BIG-NABCG collaboration. A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. The Lancet Oncology 13, e240-248
104. Liu-Chittenden Y. et al. (2012) Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes & Development 26, 1300-1305
105. Yu F.X. et al. (2014) Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell 25, 822-830
106. Bao Y. et al. (2011) A cell-based assay to screen stimulators of the Hippo pathway reveals the inhibitory effect of dobutamine on the YAP-dependent gene transcription. The Journal of Biochemistry 150, 199-208
107. Rosenbluh J. et al. (2012) β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 151, 1457-1473
108. Wang Z. et al. (2014) Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proceedings of the National Academy of Sciences of the United States of America 111, E89-E98